Blennow K - Search Results

1

Clearance systems in the brain-implications for Alzheimer disease.

Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Ménard J, Zetterberg H, Wisniewski T, de Leon MJ. Tarasoff-Conway JM, et al. Among authors: blennow k. Nat Rev Neurol. 2015 Aug;11(8):457-70. doi: 10.1038/nrneurol.2015.119. Epub 2015 Jul 21. Nat Rev Neurol. 2015. PMID: 26195256 Free PMC article. Review.

2

Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors.

Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blennow K, et al. Acta Neurol Scand. 1990 Apr;81(4):323-6. doi: 10.1111/j.1600-0404.1990.tb01563.x. Acta Neurol Scand. 1990. PMID: 2360400

3

Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

Blennow K, Hesse C, Fredman P. Blennow K, et al. Neuroreport. 1994 Dec 20;5(18):2534-6. doi: 10.1097/00001756-199412000-00032. Neuroreport. 1994. PMID: 7696597

4

The neurochemistry of Alzheimer's disease.

Blennow K, Cowburn RF. Blennow K, et al. Acta Neurol Scand Suppl. 1996;168:77-86. doi: 10.1111/j.1600-0404.1996.tb00378.x. Acta Neurol Scand Suppl. 1996. PMID: 8997425 Review.

5

A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia.

Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, Gottfries CG, Blennow K. Skoog I, et al. Among authors: blennow k. Neurology. 1998 Apr;50(4):966-71. doi: 10.1212/wnl.50.4.966. Neurology. 1998. PMID: 9566380

6

Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease.

Lidström AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K. Lidström AM, et al. Among authors: blennow k. Exp Neurol. 1998 Dec;154(2):511-21. doi: 10.1006/exnr.1998.6892. Exp Neurol. 1998. PMID: 9878186

7

Both total and phosphorylated tau are increased in Alzheimer's disease.

Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granérus AK, Vanderstichele H, Vanmechelen E, Blennow K. Sjögren M, et al. Among authors: blennow k. J Neurol Neurosurg Psychiatry. 2001 May;70(5):624-30. doi: 10.1136/jnnp.70.5.624. J Neurol Neurosurg Psychiatry. 2001. PMID: 11309456 Free PMC article.

8

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

Sjögren M, Davidsson P, Wallin A, Granérus AK, Grundström E, Askmark H, Vanmechelen E, Blennow K. Sjögren M, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2002;13(2):112-8. doi: 10.1159/000048642. Dement Geriatr Cogn Disord. 2002. PMID: 11844893

9

The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease.

Zetterberg H, Nexö E, Regland B, Minthon L, Boson R, Palmér M, Rymo L, Blennow K. Zetterberg H, et al. Among authors: blennow k. Clin Chem. 2003 Jul;49(7):1195-8. doi: 10.1373/49.7.1195. Clin Chem. 2003. PMID: 12816923 No abstract available.

10

CSF markers for incipient Alzheimer's disease.

Blennow K, Hampel H. Blennow K, et al. Lancet Neurol. 2003 Oct;2(10):605-13. doi: 10.1016/s1474-4422(03)00530-1. Lancet Neurol. 2003. PMID: 14505582 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,072 results

Search Page